TheraRadar
Clinical-Stage Companies / Gan and Lee Pharmaceuticals, U

Gan and Lee Pharmaceuticals, U

Pre-Approval PRO BETA
28
Total Trials
3
Phase 3
8
Phase 2
5
Recruiting
179
Score

Pipeline by Phase

Phase 3
3
Phase 2
8
Phase 1
20

Therapeutic Focus

Type 2 Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Healthy Subjects

Clinical Trials (28)

NCT03371082 Phase 3 COMPLETED

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research

Started: 10/31/2017

NCT03371108 Phase 3 COMPLETED

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research

Started: 10/31/2017

NCT04254380 Phase 3 WITHDRAWN

Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro

Started: 12/4/2019

NCT06558708 Phase 2 RECRUITING

A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD

Started: 6/28/2024

NCT06256562 Phase 2 COMPLETED

A Study of GZR18 Injection in Obese/Overweight Patients

Started: 6/8/2023

NCT06737042 Phase 2 NOT YET RECRUITING

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

Started: 2/12/2025

NCT06202079 Phase 2 COMPLETED

A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus

Started: 8/11/2023

NCT06199505 Phase 2 COMPLETED

A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM

Started: 11/21/2023

NCT07242664 Phase 1 RECRUITING

Clamp Study to Estimate the Relative Potency of GZR33 Versus Insulin Degludec at Steady State

Started: 10/13/2025

NCT07146347 Phase 1 RECRUITING

Comparison Study of Insulin GZR4 With Insulin Degludec

Started: 8/15/2025

NCT06548906 Phase 1 RECRUITING

A Study of GZR4 Injection at Different Injection Sites

Started: 5/8/2024

NCT06547502 Phase 1 COMPLETED

Pharmacokinetics and Safety Profile of a Single Dose GZR4 in Subjects with Renal Impairment

Started: 7/3/2024

NCT06670209 Phase 1 NOT YET RECRUITING

A Phase I Clinical Study to Evaluate the Effect of GZR18 Injection on the Pharmacokinetics of Oral Metformin Hydrochloride Tablets in Overweight/Obese Subjects

Started: 10/30/2024

NCT06548932 Phase 1 COMPLETED

A Study to Evaluate the Safety, Tolerance, PK and PD Parameters of GZR33 and GZR101 in Healthy Male Adult Subjects

Started: 6/30/2022

NCT06556641 Phase 1 COMPLETED

A Clinical Study of GZR33 and GZR101 in Healthy Subjects

Started: 12/17/2022

NCT06553248 Phase 1 COMPLETED

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 Diabetes

Started: 3/22/2023

NCT06554054 Phase 1 ACTIVE NOT RECRUITING

A Study of GZR18 Tablet in Chinese Healthy Subjects

Started: 4/1/2024

NCT06548997 Phase 1 COMPLETED

A Phase I Study of GZR18 Injection in Healthy Subjects

Started: 12/2/2021

NCT06548945 Phase 1 COMPLETED

A Phase I Study of GZR18 Injection in Obese/Overweight Subjects

Started: 4/25/2023

NCT06548815 Phase 1 COMPLETED

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single-dose GZR4

Started: 8/29/2022

NCT06256536 Phase 1 COMPLETED

A Study of GZR18 Injection in Chinese Obese/Overweight Patients

Started: 7/14/2022

NCT06256523 Phase 1 COMPLETED

A Study of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM)

Started: 6/29/2022

NCT05328726 Phase 1 COMPLETED

Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects

Started: 3/8/2022

NCT04444427 Phase 1 COMPLETED

Evaluation of GLR2007 for Advanced Solid Tumors

Started: 7/15/2020

NCT04237129 Phase 1 COMPLETED

PK/PD Study of Gan & Lee Insulin Aspart Injection vs. US & EU NovoLog®/NovoRapid® in Healthy Males

Started: 8/27/2019

NCT04235439 Phase 1 COMPLETED

PK/PD Biosimilarity Study of Gan & Lee Insulin Lispro Injection vs. EU and US Humalog® in Healthy Males

Started: 4/23/2019

NCT04236895 Phase 1 COMPLETED

PK/PD Biosimilarity Study of Gan & Lee Insulin Glargine Injection vs.US & EU Lantus® in Type 1 Diabetes Mellitus Patients

Started: 7/10/2018

NCT02506647 Phase 1 COMPLETED

PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes

Started: 12/1/2015

Drug Candidates

GZR-33 GZR18 GZR4 injection Tirzepatide GZR4 Injection Insulin Degludec GZR101 insulin degledec/insulin aspart GZR4 GZR18 and metformin
Activity Status: Active
Last Trial Started: 10/13/2025
Last Trial Ended: 9/5/2024
Trials (12 months): 2
Completed Trials: 20
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.